Cellectar Biosciences, Inc. (CLRB) 股票分析

公司概述

Cellectar Biosciences, Inc. (CLRB) operates as a clinical biopharmaceutical entity dedicated to the discovery, development, and commercialization of therapeutic drugs specifically targeting cancer treatment within the United States market. The company functions within the healthcare sector and the biotechnology industry, where its primary strategic focus involves advancing lead phospholipid drug conjugate candidates for oncology applications. As of the latest available data, the enterprise maintains a market capitalization of $11.96M, employs 11 staff members, and reports no annual revenue figures due to its developmental stage. The current market cap of $11.96M combined with the absence of reported revenue indicates that the company is an early-stage biotechnology firm whose valuation is derived primarily from the potential of its pipeline assets, specifically its Phase 2 lead candidate CLR 131 (iopofosine I-131), rather than from current cash generation.

财务健康

The financial statements for Cellectar Biosciences, Inc. reflect a net income (TTM) of $-21,791,036 and an EBITDA of $-22,766,248, while revenue (TTM) is not available. The significant gap between the reported net income loss and the EBITDA figure suggests that the company's cost structure includes substantial non-operating expenses or interest costs that are not captured in the EBITDA metric, highlighting a heavy reliance on external funding to sustain operations. The company recorded a free cash flow of $-16,425,541, which indicates a continuous consumption of cash reserves that limits immediate financial flexibility for R&D expansion or commercialization without further capital raises. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that typically signifies that the company has not yet generated positive gross revenue or that revenue recognition methods in the biotech sector do not currently result in standard margin calculations for a pre-commercial product. On the balance sheet, the company holds $13.20M in cash against $409,586 in debt, resulting in a debt-to-equity ratio of 4.13, which points to a highly leveraged position relative to its equity base given the negative equity implied by the losses. Despite the leverage, the current ratio stands at 2.96, suggesting that the company possesses sufficient current assets to cover its short-term liabilities, providing a buffer against immediate liquidity pressures. Furthermore, the return on equity is -170.3% and the return on assets is -71.0%, metrics that reveal that management has not yet generated positive returns on the capital invested by shareholders or the company, consistent with the burn rate of a clinical-stage development program.

估值评估

The valuation metrics for CLRB include a P/E Ratio (TTM) that is not applicable due to negative earnings and a forward P/E of -0.91. The discrepancy between the non-applicable trailing P/E and the negative forward P/E implies that analysts or market models project the company will not achieve profitability in the near term, rendering traditional earnings-based valuation multiples ineffective for assessing value. The price-to-book ratio is 1.49, indicating that the market values the company at a premium of 49% above its book value, which may reflect the intangible value of its intellectual property and clinical pipeline despite current losses. Alternative valuation metrics such as the price-to-sales ratio, which is not available, and the EV/EBITDA of -0.05, further complicate standard valuation comparisons as the negative EV/EBITDA confirms that the enterprise value is heavily weighted by the company's cash position relative to its negative earnings. The stock has traded between a 52-week high of $20.70 and a 52-week low of $2.43, meaning the current trading environment has seen extreme volatility within this specific range. The beta value of 0.40 indicates that the stock's price volatility is significantly lower than the broader market, suggesting it moves less than half as much as the overall market index in response to general market fluctuations.

Growth & Income

Revenue growth (YoY) and earnings growth (YoY) are both listed as not available, which precludes a direct comparison of earnings growth rates against revenue growth rates in the traditional sense. Since the company does not pay a dividend, the dividend yield is not applicable and the payout ratio is 0.0%, meaning the company retains all generated cash to fund its operations and clinical trials rather than distributing income to shareholders. Consequently, the company reinvests its earnings, or more accurately in this case, its cash reserves and potential future earnings, entirely back into the growth of its cancer treatment pipeline and operational infrastructure. The overall growth and income profile of Cellectar Biosciences, Inc. is characterized by a lack of historical growth data and no current income distribution, positioning the investment thesis strictly on the potential future commercial success of its lead phospholipid drug conjugate candidate CLR 131.